HEALTHCARE & PHARMACEUTICALS MARKET RESEARCH
Category: Virology
-
Respiratory Syncytial Virus; market value at US$9.53 billion
Respiratory Syncytial Virus (RSV) is a common and highly contagious virus that infects the respiratory tract, primarily affecting the lungs and airways.
-
Paxlovid: The Ultimate Antiviral Pill
Introduction Paxlovid, the pill that has become the go-to treatment for COVID-19 treatment, was granted full approval in May by the Food And Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, including hospitalization and death. The drug also remains available to everyone 12 and older (weighing at…
-
HERE’S WHAT WE KNOW ABOUT COVID-19 AND AUTOIMMUNITY
Before we get into understanding the possible links between autoimmunity and COVID-19, it is imperative that we understand what autoantibodies are and how they affect our body. These self-attacking antibodies are produced by the immune system and are pathogenic in nature as they can destroy the antigens and other substances such as carbohydrate,proteins, etc. made by…
-
NIPAH VIRUS : ALL THE INFORMATION YOU NEED
History of the Nipah virus in India In 2001, the first outbreak of Nipah virus was occurred in West Bengal that caused as many as 45 deaths. Again, it happened there in 2007 and 5 people lost their lives. In Kozhikode, it all started in May, 2018 when the first Nipah virus disease outbreak was…
-
FIRST DEATH DUE TO NIPAH VIRUS IN KERALA
A 12 year old boy, Muhammad Hashim dies of Nipah virus in Kozhikode on Sunday morning. The Central Government has confirmed the case and a team of National Centre for Disease Control was rushed to kerala for technical support. Kerala’s health minister, Veena George has also went to assess the situation. A team including health…
-
ACTIVE COVID-19 CASES CROSS THE 2 LAKH MARK IN KERALA
With a daily count of over 30,000 cases for the fourth consecutive day, Kerala accounts for around 70% of he total COVID-19 cases in the country. Active cases are over 2 lakhs and the latest positivity rate recorded on a day was 18.67%. “Since the relaxations in lockdown, there has been surge in cases. It was further increased after Onam,” says Vijayan…
-
Pfizer-BioNTech vaccine becomes the first vaccine to receive full FDA validation
The vaccine by Pfizer-BioNTech is the first vaccine that has been lincensed for COVID-19. The mRNA vaccine has shown to prevent 95 percent of COVID-19 during the clinical trials and can be administered in people aged 16 and older. It has also been given emergency use authorisation for use in adolescents in December last year. The two dose vaccine can be given…
-
ZyCoV-D : FIRST VACCINE FOR CHILDREN IN INDIA
Zydus Cadila’s DNA based vaccine ZyCoV-D becomes the first vaccine to receive emergency use authorization for children above 12 years of age. The three-dose vaccine has an efficacy rate of 66.6 per cent as per the trials conducted across the nation. Zydus’ needle free vaccine is only the second vaccine that is being produced in…
-
LAMBDA : NEW VARIANT WITH 7 MUTATIONS
Lambda, a new coronavirus variant has been declared as a “variant of interest” by the World Health Organization (WHO). 31 countries including United States, United Kingdom, France, Italy, Germany and Switzerland etc., have reported the cases of this variant. Originated in Peru in December 2020, now this particular variant accounts for almost 82% of the total…
-
INDIA ADMINISTERED OVER 32 CRORE DOSES, OVERTAKES US
Health ministry on Monday informed that as many as 32.8 crore doses of Covid-19 vaccines have been administered since the start of the vaccination drive that began from January 16. Out of these, one crore healthcare workers took the first dose and 72 lakh got the second dose as well. Following a new policy, India has…
Follow Us
Recent Posts
-
Bedaquiline Role in Treating Tuberculosis having a hefty $1.38 billion dollar market
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
-
Semaglutide’s massive influence on the Diabetes Pharmaceutical Market and 6 competitors
-
FDA approved Leqembi to have $12.9 billion sales
-
Assistive Technology Market; a $82B Growth Story
Tags
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila